Login
Companies $ONCO
$3.21 +$0.00 (0.0%) After hours
Onconetix, Inc. logo

Onconetix, Inc.

onconetix.com

What Do They Do?

Sells Proclarix, a protein-based blood test used with prostate-specific antigen testing to help doctors assess prostate cancer risk, to diagnostic laboratories, hospitals and medical centers.

How Do They Make Money?

Customers buy Proclarix, with product sales counted when the product is transferred. Proteomedix bills life-sciences customers for development work as it is performed and earns license revenue by granting intellectual-property rights, counted when those rights transfer.

FY2025 revenue

Who Are Their Customers?

Proclarix is sold directly to end users such as laboratories, hospitals and medical centers, and to distributors. Tests are run through hospital or commercial laboratories serving clinical urology centers; lab networks also reach urologists and general practitioners in private practice.

Do Revenues Turn Into Profits?

No. It lost $14M in FY2025.

Operating income, FY2025
−2190% of revenue
▲ +68% (Loss) vs FY2024 (−$56.5M, −2238%)
Net income, FY2025
−1721% of revenue
▲ +76% (Loss) vs FY2024 (−$58.7M, −2325%)
Free cash flow, FY2025
−1187% of revenue
▲ +8% (Loss) vs FY2024 (−$10.5M, −417%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −260% (Loss)
vs −$8.8M in Q3 FY2025
  • Nov 4, 2026 Onconetix and Realbotix amended their pending share-exchange agreement The amendment extends the agreement’s end date to March 31, 2027, and changes the seller’s ownership share if closing net cash is below $12.5 million.
  • Apr 20, 2026 The board chair resigned and another director became chair Andrew Oakley resigned as board chair, and the board appointed Sammy Dorf as chairman.

From vaccine research to prostate diagnostics The older report described preventive vaccine research across infectious diseases and a vaccine pipeline; the latest report focuses on commercializing Proclarix, a prostate cancer blood test, and says vaccine discovery and development programs were halted.

Who Do They Compete With?

Competes with Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, OPKO Health, Cleveland Diagnostics, Gen-Probe, Hologic, MdxHealth, Exosome Diagnostics, Bio-Techne, and A3P Biomedical

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support